Probionov   Report issue

For profit Phase 3
Founded: Clermont-Ferrand France (1955)
Status: No NME R&D (1955)

Organization Overview

First Clinical Trial
2014
NCT02251093
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

lactobacillus casei (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidiasis (Phase 3)

Candidiasis, Vulvovaginal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1